Fmoc-L-threonine is charged into automated solid-phase peptide synthesizers as a β-branched Fmoc amino acid with a free secondary hydroxyl group. The compound is dissolved in dimethylformamide at 0.2-0.4 M concentration for standard amino acid cartridges on automated peptide synthesizers with UV feedback control. Coupling is performed with N,N'-diisopropylcarbodiimide and ethyl (hydroxyimino)cyanoacetate at a 1:1:1 molar ratio relative to resin substitution in dimethylformamide at 25°C. The β-branched side chain slows acylation; preactivation of 3-5 min and coupling of 30-60 min are used to reach complete acylation on resin. Unreacted amino groups are capped with acetic anhydride in pyridine/dimethylformamide at 1:2:3 v/v/v before the next amino acid cycle. Fmoc removal is carried out with 20% v/v piperidine in dimethylformamide in two cycles of 10 min and 5 min. The dibenzofulvene-piperidine adduct is quantified by UV absorbance at 301 nm; cumulative deprotection is maintained above 99% before each chain extension. Final cleavage from polyethylene glycol-polystyrene or aminomethyl resin is performed with trifluoroacetic acid/water/triisopropylsilane at 95:2.5:2.5 v/v/v for 2.5-3 h at 25°C, followed by precipitation in cold methyl tert-butyl ether and preparative reversed-phase HPLC on C18 silica columns with 5 µm particles and 250 × 21.2 mm column geometry. The resulting final products are lyophilized peptide acetate APIs and peptide fragments for therapeutic peptide assembly, with residual water controlled below 5% by Karl Fischer titration. Manufacturing records under ICH Q7 govern this route, HPLC purity is determined according to USP <621>, and specification limits follow ICH Q6A. The operational boundary is the unprotected β-hydroxy group: repeated forced activation with aminium/phosphonium reagents at temperatures above 30°C increases the risk of O-acylation, and for sequences with multiple threonine residues the tert-butyl-protected analogue is preferred. Unprotected Fmoc-L-threonine is therefore reserved for short fragments and solution-phase segment condensation where side-chain protection is not required throughout the full sequence.

When Fmoc-L-Threonine Is Coupled as an Unprotected β-Hydroxy Residue in Glycopeptide Assembly

Fmoc-L-threonine is used in the synthesis of O-linked glycopeptide fragments for mucin-based cancer vaccine research because the side-chain hydroxyl is the glycosylation acceptor. In a published on-resin route, the protected peptide is assembled with Fmoc-Thr-OH at the target residue, and the resin-bound free hydroxyl is treated with peracetylated D-galactosamine trichloroacetimidate in anhydrous dichloromethane at -20°C to 0°C for 2-4 h in the presence of trimethylsilyl trifluoromethanesulfonate at 0.2-0.5 equiv relative to the glycosyl donor. After glycosylation, the resin is washed with dichloromethane and dimethylformamide, and the remaining Fmoc group is removed with 20% piperidine in dimethylformamide to continue chain elongation if required. Final cleavage uses trifluoroacetic acid/water/triisopropylsilane at 95:2.5:2.5 v/v/v for 3 h at 25°C, followed by precipitation in cold methyl tert-butyl ether and semi-preparative RP-HPLC purification on C18 silica with a 0.1% trifluoroacetic acid acetonitrile gradient. The primary final products are synthetic mucin tandem-repeat glycopeptide candidates and O-linked glycan positional isomers used in mass spectrometric fragmentation libraries. Compliance for this route is governed by ICH Q11 when scaled beyond exploratory chemistry, with residual solvent limits specified in ICH Q3C and purity determination according to USP <621>. The main operational limitation is that unprotected Fmoc-L-threonine is practical only for O-glycans that can be introduced directly on the resin, because the unprotected hydroxyl can be acetylated during capping or acylated during chain elongation. For complex sialylated O-glycans, pre-glycosylated Fmoc-threonine derivatives are generally used, and published data for direct on-resin sialylation with free threonine is limited.

Peptide microarrays fabricated by SPOT synthesis on amino-functionalized cellulose membranes use Fmoc-L-threonine as the building block for defined threonine-containing peptide spots. The compound is dissolved at 0.3 M in N-methylpyrrolidone with ethyl (hydroxyimino)cyanoacetate and diisopropylcarbodiimide for deposition at 0.2-0.5 µL per spot through automated liquid handling. Coupling proceeds for 20 min at 25°C, followed by capping with acetic anhydride and Fmoc deprotection with 20% piperidine in dimethylformamide. The free β-hydroxy group is retained during array assembly to avoid the need for tert-butyl deprotection before downstream serological or enzymatic assay. After complete peptide chain assembly, side-chain protecting groups are removed with 95:2.5:2.5 trifluoroacetic acid/water/triisopropylsilane v/v/v for 1.5 h, and the membrane is dried under vacuum before storage in dry nitrogen. Final products are cellulose- or glass-bound peptide microarrays used for serum antibody epitope mapping, kinase substrate profiling, and phage display hit verification. Compliance for diagnostic development is maintained under ISO 13485:2016 and 21 CFR 820, with lot release testing of spot density by amino acid analysis and MALDI-TOF mass spectrometry. Operational boundaries include spot-to-spot heterogeneity caused by free hydroxyl interference with ester activation on cellulose; membranes exposed to relative humidity above 60% require pre-drying before spotting, and published data for this specific SPOT configuration with unprotected threonine is limited.

Why Is On-Resin Phosphorylation More Efficient with Unprotected Fmoc-Thr-OH?

Fmoc-L-threonine provides a direct substrate for on-resin phosphitylation because the β-hydroxy group is available for electrophilic phosphorylation without the need to remove tert-butyl ether protection before phosphopeptide assembly. The resin-bound peptide is elongated with standard Fmoc chemistry, and the threonine hydroxyl is treated with dibenzyl N,N-diisopropylphosphoramidite at 10-15 equiv and 0.3 M 1H-tetrazole in anhydrous dichloromethane for 30-45 min under argon at 25°C. The resulting phosphite triester is oxidized to the protected phosphate triester with 5.5 M tert-butyl hydroperoxide in decane for 60 min at 25°C. After oxidation, the peptide is cleaved with 95:2.5:2.5 trifluoroacetic acid/water/triisopropylsilane v/v/v for 3 h to remove benzyl phosphate protecting groups and resin linkers simultaneously. The crude pThr-containing peptide is precipitated in diethyl ether, dissolved in 0.1% aqueous trifluoroacetic acid, and purified by RP-HPLC on C18 columns with 5 µm particles. Final products include phosphothreonine peptide standards for mass spectrometry-based kinase activity assays and substrate peptides for cell-free kinase reaction monitoring. Reference materials produced under this route are controlled under ISO 17034:2016, and testing laboratories use ISO/IEC 17025:2017 for quantification by LC-MS/MS; residual solvents comply with ICH Q3C. The phosphitylation step is sensitive to moisture and must be conducted under inert atmosphere with predried solvents; incomplete oxidation yields phosphite triester intermediates that appear as mass shifts and are removed by preparative HPLC. Published data for large-scale batch yields in this specific phosphitylation configuration is limited.

Low-Molecular-Weight Hydrogel Processing with Fmoc-Thr-OH

Fmoc-L-threonine belongs to the class of Fmoc-amino acid low-molecular-weight gelators that form self-assembled fibrillar networks through π-π stacking of the fluorenylmethoxycarbonyl moieties and hydrogen bonding of the amino acid head groups. In processing, the compound is dissolved in alkaline water at pH 8-10, often with 0.1 M sodium hydroxide or sodium carbonate, and gelation is triggered by lowering the pH to 7.0-7.4 with glucono-δ-lactone or dilute hydrochloric acid. The threonine β-hydroxy group provides additional inter-fibril hydrogen bonding, which alters the critical gelation concentration and fibril bundling compared with Fmoc-phenylalanine. Reported critical gelation concentrations for Fmoc-amino acid gels generally fall between 0.1 wt% and 5.0 wt% depending on buffer type and ionic strength, but published data for Fmoc-L-threonine gelation is less extensive than for Fmoc-phenylalanine and should not be transferred without pilot measurement. Final products are fibrillar hydrogels used as cell culture scaffolds, peptide delivery matrices, and rheological models for supramolecular assembly. Biomedical prototypes are screened for cytocompatibility by direct contact and extract dilution using ISO 10993-5:2009 and ISO 10993-12:2021; hydrogel viscoelasticity is measured by oscillatory rheometry in plate-plate geometry at 37°C with 0.1-1 Hz frequency sweep to establish storage modulus values. Operational boundaries include thermoreversibility and collapse at elevated ionic strength above 150 mM sodium chloride. Sterilization by autoclaving is not recommended because the supramolecular structure is heat-labile; filtration at 0.22 µm or gamma irradiation at 25 kGy is used where microbial control is required.

A production route for peptide-drug conjugate intermediates uses Fmoc-L-threonine in the synthesis of peptide scaffolds with a free β-hydroxy group for subsequent esterification to polyethylene glycol, biotin, or cytotoxic linker moieties. The peptide is assembled on 2-chlorotrityl chloride resin using Fmoc-L-threonine as the terminal or internal residue, and the free hydroxyl is esterified with diglycolic anhydride in dimethylformamide containing 1,8-diazabicyclo[5.4.0]undec-7-ene at 2 equiv for 4 h at 25°C. Excess anhydride is removed by filtration, and the resin-bound peptide is cleaved with 20% hexafluoroisopropanol in dichloromethane for 30 min to preserve side-chain protecting groups. The purified peptide conjugates are used as linkers for target binding and cellular uptake studies, as well as intermediates for antibody fragment conjugates. Compliance follows ICH Q11 for starting material characterization and ICH Q2(R1) for validation of the RP-HPLC purity method; residual solvent limits follow ICH Q3C for dichloromethane and dimethylformamide. Process boundaries: the esterification step is selective only when the N-terminus and other nucleophilic side chains remain protected; free amino groups would otherwise compete for acylation. Published data for this specific conjugate configuration is limited.